A combination of lisocabtagene maraleucel (liso-cel, Breyanzi) plus ibrutinib (Imbruvica) demonstrated a trend for better ...

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate ...

RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.

The FDA issued a Complete Response Letter for Regeneron’s biologics license application for odronextamab, a bispecific antibody targeting CD20 and CD3 for the treatment of relapsed or refractory ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron ...

Local pharma stocks were rocky on Friday after President Donald Trump directed major drugmakers to reduce the cost of their ...

The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...

The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Regeneron (CRL) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory ...

Late last week, President Donald Trump sent letters to 17 pharmaceutical companies pressing them to deliver on his May ...